Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Kazunori AokiYukari NishitoNoriko MotoiYasuhito AraiNobuyoshi HiraokaTatsuhiro ShibataYukiko SonobeYoko KayukawaEri HashimotoMina TakahashiEtsuko FujiiTakashi NishizawaHironori FukudaKana OhashiKosuke AraiYukihiro MizoguchiYukihiro YoshidaShun-Ichi WatanabeMakiko YamashitaShigehisa KitanoHiromi SakamotoYuki NagataRisa MitsumoriKouichi OzakiShumpei NiidaYae KanaiAkiyoshi HirayamaTomoyoshi SogaToru MaruyamaKeisuke TsukadaNami YabukiMei ShimadaTakehisa KitazawaOsamu NatoriNoriaki SawadaAtsuhiko KatoTeruhiko YoshidaKazuki YasudaHideaki MizunoHiroyuki TsunodaAtsushi OchiaiPublished in: Cancer research communications (2023)
The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.